3OCG

P38 Alpha kinase complexed with a 5-amino-pyrazole based inhibitor

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.21 Å
  • R-Value Free: 0.270 
  • R-Value Work: 0.212 
  • R-Value Observed: 0.214 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history. 


Literature

5-Amino-pyrazoles as potent and selective p38α inhibitors

Das, J., Moquin, R.V., Dyckman, A.J., Li, T., Pitt, S., Zhang, R., Shen, D.R., McIntyre, K.W., Gillooly, K., Doweyko, A.M., Newitt, J.A., Sack, J.S., Zhang, H., Kiefer, S.E., Kish, K., McKinnon, M., Barrish, J.C., Dodd, J.H., Schieven, G.L., Leftheris, K.

(2010) Bioorg Med Chem Lett 20: 6886-6889

  • DOI: 10.1016/j.bmcl.2010.10.034
  • Primary Citation of Related Structures:  
    3OCG

  • PubMed Abstract: 

    • The synthesis and structure-activity relationships (SAR) of p38α MAP kinase inhibitors based on a 5-amino-pyrazole scaffold are described. These studies led to the identification of compound 2j as a potent and selective inhibitor of p38α MAP kinase with excellent cellular potency toward the inhibition of TNFα production ...

    The synthesis and structure-activity relationships (SAR) of p38α MAP kinase inhibitors based on a 5-amino-pyrazole scaffold are described. These studies led to the identification of compound 2j as a potent and selective inhibitor of p38α MAP kinase with excellent cellular potency toward the inhibition of TNFα production. Compound 2j was highly efficacious in vivo in inhibiting TNFα production in an acute murine model of TNFα production. X-ray co-crystallography of a 5-amino-pyrazole analog 2f bound to unphosphorylated p38α is also disclosed.

    Organizational Affiliation: 

    Bristol-Myers Squibb Research and Development, Princeton, NJ 08543-4000, USA. jagabandhu.das@bms.com



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Mitogen-activated protein kinase 14A366Homo sapiensMutation(s): 0 
Gene Names: CSBP, CSBP1, CSBP2, CSPB1, MAPK14, MXI2, SAPK2A
EC: 2.7.11.24
UniProt & NIH Common Fund Data Resources
Find proteins for Q16539 (Homo sapiens)
Explore Q16539 
Go to UniProtKB:  Q16539
PHAROS:  Q16539
GTEx:  ENSG00000112062 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ16539
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
OCG
Query on OCG
Download Ideal Coordinates CCD File 
B [auth A]5-amino-N-[5-(isoxazol-3-ylcarbamoyl)-2-methylphenyl]-1-phenyl-1H-pyrazole-4-carboxamide
C21 H18 N6 O3
DMYYPSLMFSEFCK-UHFFFAOYSA-N		 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
OCG PDBBind:  3OCG IC50: 3 (nM) from 1 assay(s)
BindingDB:  3OCG IC50: 3 (nM) from 1 assay(s)
Binding MOAD:  3OCG IC50: 3 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.21 Å
  • R-Value Free: 0.270 
  • R-Value Work: 0.212 
  • R-Value Observed: 0.214 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 67.94α = 90
b = 71.43β = 90
c = 80.55γ = 90
Software Package:
Software NamePurpose
AMoREphasing
BUSTERrefinement
DENZOdata reduction
SCALEPACKdata scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


View more in-depth experimental data

Entry History 

Deposition Data

  • Deposited Date: 2010-08-10 
  • Released Date: 2010-11-17 
    • Deposition Author(s): Sack, J.S.

Revision History  (Full details and data files)

  • Version 1.0: 2010-11-17
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2020-09-02
    Changes: Database references, Derived calculations, Structure summary